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Abstract
Background: Fulminant meningococcal sepsis, characterized by overwhelming innate immune activation, mostly
affects young people and causes high mortality. This study aimed to investigate the effect of targeting two key
molecules of innate immunity, complement component C5, and co-receptor CD14 in the Toll-like receptor system,
on the inflammatory response in meningococcal sepsis.
Methods: Meningococcal sepsis was simulated by continuous intravenous infusion of an escalating dose of heat-
inactivated Neisseria meningitidis administered over 3 h. The piglets were randomized, blinded to the investigators,
to a positive control group (n = 12) receiving saline and to an interventional group (n = 12) receiving a recombinant
anti-CD14 monoclonal antibody together with the C5 inhibitor coversin.
Results: A substantial increase in plasma complement activation in the untreated group was completely abolished
in the treatment group (p = 0.006). The following inflammatory mediators were substantially reduced in plasma in
the treatment group: Interferon-γ by 75% (p = 0.0001), tumor necrosis factor by 50% (p = 0.01), Interleukin (IL)-8 by
50% (p = 0.03), IL-10 by 40% (p = 0.04), IL-12p40 by 50% (p = 0.03), and granulocyte CD11b (CR3) expression by 20%
(p = 0.01).
Conclusion: Inhibition of C5 and CD14 may be beneficial in attenuating the detrimental effects of complement
activation and modulating the cytokine storm in patients with fulminant meningococcal sepsis.
Keywords: Endotoxin, Chemokines, Complement, Cytokines, Immune response, Neisseria meningitidis, Septic shock,
Toll-like receptor
Background
Fulminant meningococcal sepsis is a rapid and devastating
infection caused by Neisseria meningitidis, characterized
by whole-body inflammation and severe disturbances in
homeostasis leading to high mortality despite optimal
antimicrobial and intensive care treatment [1–3]. Within
12–24 h after onset of the first symptoms, the number of
meningococci in the circulation may reach levels as high
as 108/mL in the plasma [3]. A massive and complex in-
flammatory response is triggered, which in turn is harmful
to the body and leads to multi-organ failure [1–3].
Treatment-resistant septic shock caused by profound
vasodilation and declining cardiac function is the principal
cause of death [1–3]. Activation of TLR4-MD2 by
lipopolysaccharide (LPS) is considered the most important
inflammatory mechanism in meningococcal sepsis [4, 5].
However, different clinical trials aiming to reduce the
inflammatory response caused by LPS have failed to
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improve the outcome in patients with severe sepsis.
This includes studies attempting to neutralize LPS or
attenuate the response to LPS by blocking different
steps of the inflammatory mechanisms, including
binding of LPS to TLR4-MD2 or blocking the effect
of individual inflammatory mediators like IL-1β and
tumor necrosis factor (TNF) [6–9].
Molecular structures of meningococci other than
LPS activate different parts of the innate immune sys-
tem, including the complement system and additional
TLRs beside TLR4-MD2 [10]. CD14 serves as a co-
factor for several of the TLRs, including TLR4 and TLR2
[11, 12]. Complement is a plasma cascade system with
diverse inflammatory effects, driven mainly by activa-
tion products which react with leukocyte surface re-
ceptors [13, 14]. It can be activated through three
initial routes, namely the classical, lectin, and alterna-
tive pathway. Activation of all three initial pathways
merges and leads to activation of the common com-
plement factors C3 and C5. Further, activation of C5
leads to formation of C5a and the terminal C5b-9
complex (TCC) [15]. C5a is a potent anaphylatoxin
with diverse inflammatory effects including stimulation of
cytokine production, upregulation of adhesion molecules,
paralysis of neutrophils, and increased vascular permeabil-
ity [16]. TCC incorporates into bacterial lipid membranes
as the membrane attack complex and may cause lysis of
pathogens, in particular Neisseria species. TCC may also
be formed in the fluid phase as a soluble form (sC5b-9)
and then serves as a valuable marker of complement
activation.
We have hypothesized that a combined inhibition
of complement and CD14 will efficiently attenuate
the inflammatory response in various clinical situa-
tions including sepsis [17]. Previously, we demon-
strated that upstream inhibition of the inflammatory
response by combined blocking of CD14 and com-
plement strongly attenuates a wide range of inflam-
matory responses induced by meningococci in an ex
vivo whole blood model [10]. A reinforced inhibitory
effect on a broad spectrum of inflammatory
mediators by the combined inhibition has recently
also been proven in porcine E. coli induced sepsis
[18] and mouse and pig polymicrobial sepsis where
survival was also increased [19, 20].
The aim of the present study was to investigate
the effect of blocking both C5 and CD14 on the in-
flammatory response induced in vivo in a porcine
model of meningococcal sepsis. The model has been
developed by our group as the first large animal
model simulating meningococcal sepsis and has been
proven to be a valuable tool to study inflammatory
mechanisms of the disease and potential interven-
tions [5, 21, 22].
Methods
Interventional drugs
For inhibition of porcine CD14, a recombinant variant of
a well-established anti-porcine CD14 mouse monoclonal
IgG2b antibody (Mil2) was used. This novel anti-porcine
CD14 antibody (rMIL2) was recently constructed by our
group as a mouse-human chimeric, IgG2/IgG4 hybrid
antibody keeping the antigen binding site the same as for
Mil2 [23]. Thus, rMIL2 exerts comparable ex vivo and in
vivo CD14 binding and inhibition efficacies as the original
murine clone, demonstrated by competitive binding tests
and cytokine release assays. The original Mil2 clone was
used in our initial intervention studies of porcine sepsis
[18, 24–26]. The inflammatory response was successfully
inhibited, but this clone was hampered by undesired effect
or functions mediated by the IgG2b Fc part of Mil2 and
consequently induced an anaphylactoid-like reaction. In
contrast, the IgG2/4 rMIL2 was completely inert with re-
spect to such functions [22] and successfully used in a
subsequent study [20] and in the present one. Endotoxin-
free recombinant OmCI (coversin), a 16.8-kDa protein,
was provided by Akari Therapeutics Plc (London, UK)
[27].
Bacteria
The international reference strain N. meningitidis 44/76
(H44/76) was obtained from the National Institute of
Public Health, Oslo, Norway. It is characterized as
B:15:P1.7,16:L3,7,9 and was originally isolated from a
female patient with lethal meningococcal septic shock
[28]. Meningococci were grown overnight on Columbia
agar and resuspended in sterile PBS. For safety reasons,
bacteria were heat inactivated at 57 °C for 30 min, and
then frozen at −70 °C until used.
Animals and experimental groups
Piglets (Sus scrofa domesticus, outbred stock) of either
sex, weighing 6 kg (range 5.5–6.5 kg) were used. All pig-
lets were clinically healthy and thus none were excluded
from the study. The piglets were randomized into two
groups, each consisting of 12 animals: an intervention
and a positive control group. In addition, two sham con-
trol piglets that received saline instead of bacteria were
included as reference. The groups were blinded for the
investigators. The number of piglets in each group was
decided according to previous analysis and experience
showing that at least 10 animals in each group were
needed to demonstrate differences [5, 18].
Anesthesia and surgery
The piglets were pre-medicated with 2–3 mg intranasal
midazolam at the animal housing facility before transport
to laboratory. At the laboratory, venous access was estab-
lished in one of the ears and thereafter 10–15 mg/kg
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ketamine was given intravenously (i.v.) before oral intub-
ation using a 4.9-mm inner diameter tube with cuff. After
intubation, an i.v. infusion of propofol (10 mg/kg/h) and
fentanyl (50 μg/kg/h) was started and mechanical ventila-
tion was established. A 5 F pulmonary artery catheter
(Baxter Edwards Laboratories, Irvine, CA) was inserted
via the left external jugular vein and guided into a distal
pulmonary artery by pressure wave-form analysis. A can-
nula was inserted in the left carotid artery for continuous
recording of arterial pressure and intermittent blood
sampling. A urinary catheter was inserted into the urinary
bladder via a cystotomy. After the completion of surgery
and insertion of catheters, the animals were placed on
their right side, remaining in this position for the rest of
the experiment.
Experimental design
After induction of anesthesia and surgery, the interven-
tion group received first a bolus of coversin (1 mg/kg)
and thereafter a bolus of rMIL2 (5 mg/kg), administered
about 10 min before induction of sepsis. Excess coversin
from the bolus not bound to C5 is rapidly removed from
circulation [27]. Therefore, to bind C5 synthesized by
piglets during the experiment, coversin was infused at
0.2 mg/h throughout the experimental course. Sepsis
was induced by i.v. infusion of increasing numbers of N.
meningitidis. Septic shock was obtained according to the
Third International Consensus Definitions for Sepsis
and Septic shock, as vasopressors were needed to keep
the blood pressure above 65 mmHg [29]. Due to the
influence of vasopressors, cardiovascular parameters
could not be included as scientific readouts. There was
no difference between the positive control group and the
intervention group regarding the amount of vasopres-
sors needed to keep the blood pressure above 65 mmHg.
To limit the need for inhibitors, the size of the pigs
used in the present study was reduced from about 30-kg
to about 6-kg piglets compared to previously published
studies employing the porcine model of meningococcal
sepsis [5, 21]. However, we found that in these piglets a
state of fulminant sepsis was reached within a shorter
time than in the larger animals. Thus, the observational
period was shortened from 4 h in the previous studies to
3 h in the present study.
Each piglet received a total of 8.4 × 109 bacteria/kg.
The positive control group received the same volume of
saline as the intervention group. The sham animals also
received the same volume of saline. Blood samples were
drawn before i.v. infusion of intervention agents
(Tbasis), before start of bacterial infusion (T0), and 60,
120, and 180 min after induction of sepsis (T60, T120,
and T180). All animals received the same background
infusion of Ringer’s acetate, i.e., 10 mL/kg/h during
surgery and until 60 min after induction of sepsis, and
thereafter 20 mL/kg/h to 120 min and 30 mL/kg/h to
180 min after induction of sepsis. In addition, 10%
glucose was given i.v. at 5 mL/kg/h throughout the
experimental course to avoid hypoglycemia. Inotrop and
vasopressor therapy were given when needed as a
therapy for severe and lethal hypotension.
Functional complement activity
A commercially available enzyme immune assay (Com-
plement system Screen WIESLAB®; Euro Diagnostica,
Malmö, Sweden) was used to test functional activity of
the classical complement pathway. The kit detects
human complement activity, but has been shown to
cross-react efficiently with pig [30]. Samples were ana-
lyzed in serum, prepared after 1-h clotting, centrifuged,
and immediately aliquoted and stored at −70 °C.
Complement activation
Soluble TCC (sC5b-9) was measured using multiplex
xMAP technology (Bio-Plex® Multiplex System, Bio-Rad
Laboratories, Inc. Hercules, CA) as previously described
[18, 31]. Samples were analyzed in EDTA-plasma pre-
pared immediately after blood sampling. Whole blood
was placed on crushed ice, centrifuged within 30 min at
1500 g at 4 °C for 20 min, immediately aliquoted, and
stored at −70 °C.
Cytokines
The cytokines TNF, IL-1β, IL-4, IL-6, IL-8, IL-10, and
IL-12p40 and Interferons (INF)-α and INF-γ were
analyzed in EDTA-plasma obtained as described for
soluble TCC above, using multiplex technology (Procar-
taPlex, eBioscience, Bender MedSystems GMbH, Vienna,
Austria).
Leukocyte activation
Leukocyte activation was measured by flow cytometry.
In pig whole blood, neutrophils are clearly discriminated
from mononuclear cells, but lymphocytes and mono-
cytes cannot be separated by forward/side scatter dot
plots. For measurement of wCD11R3 on neutrophils
(the pig ortholog to human CD11b), blood was collected
at Tbasis and T180, anticoagulated with EDTA, and
stained with mouse anti-porcine wCD11R3 FITC clone
2 F4/11 or the isotype-matched mouse IgG1-FITC nega-
tive control Ab (AbD Serotec, Oxford, UK). The samples
were incubated for 15 min in the dark, and red cells
were lysed with 0.16 M NH4Cl/10 mM NaHCO3-/
0.12 mM EDTA (Tritiplex III) for 8–10 min in the dark
at ambient temperature. Samples were centrifuged at
300 g for 5 min at 4 °C, and the cells were washed with
PBS, 0.1% BSA (Biotest, Dreieich, Germany). The
samples were then resuspended in PBS, 0.1% BSA before
flow cytometry (FACSCalibur; Becton Dickinson, Franklin
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Lakes, NJ). Values are given in mean fluorescence inten-
sity (MFI).
Data presentation and statistical analysis
Statistical analyses were performed with GraphPad
Prism version 6 (GraphPad Software, San Diego, CA).
The positive control group was compared with the
treatment group using two-way ANOVA. Area under
the curve (AUC) was used as a single measure of the
total difference between groups in the amount of each
cytokine secreted.
The difference in wCD11R3 upregulation on granulo-
cytes in the intervention group and the positive control
group was measured at only one time-point (T180) in
addition to baseline and was analyzed by Student’s t test.
For all statistical analyses, p < 0.05 was considered statis-
tically significant. Two sham animals were included as
references.
Results
Complement activation
TCC was used as a measure of complement activation at
the different time points during the experiment. In the
positive control group, TCC increased from mean 273
(±87; 95% CI) complement arbitrary units (CAU)/L at
T0 to mean 1233 (±871) CAU/L at T180 (p = 0.01)
(Fig. 1, upper panel), confirming systemic activation of
complement. No increase of TCC was seen in the treat-
ment group. Complete inhibition of complement activity
in the treatment group after administration of coversin
was further confirmed at T60 by the classical pathway
WIESLAB® assay, which detects the total complement
activity of the classical and terminal pathway (Fig. 1,
lower panel).
Cyotokines
IFN-γ: In the positive control group, IFN-γ increased
from <lower detection limit (LDL) at T0 to mean 16
(±7.5) pg/mL at T120 and 14 (±6.4) pg/mL at T180
(Fig. 2). In the treatment group, IFN-γ increased from
<LDL at T0 to mean 2 (±2.3) pg/mL at T120 and 8
(±5.3) pg/mL at T180. The difference between the
groups was statistically significant (p = 0.0001), and the
area under the curve (AUC) was 75% lower in the
treatment group than in the positive control group. No
increase was seen in sham animals.
TNF: In the positive control group, TNF increased from
<LDL at T0 to mean 44 (±15.1) ng/mL at T120 (Fig. 2).
Thereafter, the level declined to mean 13 (±4) ng/mL at
T180. In the treatment group, TNF increased from
<LDL to a plateau of mean 17 (±6.4 and ±10) ng/mL at
T120 and T180. The difference between the groups was
statistically significant (p = 0.01), and the AUC was 50%
lower in the treatment group than in the positive control
group. No increase was seen in sham animals.
IL-1β: In the positive control group, IL-1β increased
from <LDL at T0 to mean 0.1 (±0.05) ng/mL at T120
and 0.9 (±0.5) ng/mL at T180 (Fig. 2). In the treatment
group, IL-1β increased from <LDL at T0 to mean 0.08
(±0.01) ng/mL at T120 and 0.6 (±0.3) ng/mL at T240.
The AUC was 30% lower in the treatment group than in
the positive control group but the difference between
the groups was not significant (p = 0.2). No increase was
seen in sham animals.
Fig. 1 Upper panel: Complement activation was measured as plasma
TCC by multiplex technology at different time points during the
experiments (mean with 95% CI). The positive control group and the
group treated with coversin and rMIL2 (coversin/rMIL2) contained 12
animals each. Two sham animals are shown for comparison. Lower
panel: Complement activity of the classical pathway was measured at
different time points by the Complement system Screen WIESLAB®
assay (mean with 95% CI). Statistical significance is given for the
difference between the positive control and the treatment group
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IL-6: In the positive control group, IL-6 increased from
<LDL at T0 to mean 0.8 (±0.3) ng/mL at T120 and 2.6
(±0.9) ng/mL at T180 (Fig. 2). In the treatment group,
IL-6 increased from <LDL at T0 to mean 0.5 (±0.2)
ng/mL at T120 and 2.6 (±1.1) ng/mL at T180. The
AUC was 15% lower in the treatment group than in
the positive control group, but the difference between
the groups was not significant (p = 0.6). No increase
was seen in sham animals.
IL-8: In the positive control group, IL-8 increased from
<LDL at T0 to mean 1.8 (±1) ng/mL at T120 and 4.5
(±1.6) ng/mL at T180 (Fig. 2). In the treatment group,
IL-8 increased from <LDL at T0 to 0.4 (±0.2) ng/mL at
T120 and 3.4 (±1.7) ng/mL at T180. The difference be-
tween the groups was statistically significant (p = 0.03),
and the AUC was 50% lower in the treatment group
than the positive control group. No increase was seen in
sham animals. One animal of the treatment group
showed excessively increased IL-8 level at T180 right
before it died (83 ng/mL). This value was 33 SD higher
than the mean value of the rest of the treatment group.
Thus, it was regarded as an outlier and excluded from
statistical analysis.
IL-10: In the positive control group, IL-10 increased
from mean 0.05 (±0.01) ng/mL at T0 to 4.6 (±0.8) ng/mL
at T120 and 6.6 (±2.3) ng/mL at T180 (Fig. 2). In the
treatment group, IL-10 increased from mean 0.1 (±0.01)
to 2.8 (±0.4) ng/mL at T120 and 3.6 (±0.4) ng/mL at
T180. The difference between the groups was statistically
significant (p = 0.04), and the AUC was 40% lower in the
treatment group than the positive control group. No
increase was seen in sham animals.
Fig. 2 Plasma cytokines (INF-γ, TNF, IL-1β, IL-6, IL-8, IL-10, and IL12p40) were measured by multiplex technology at different time points during
the experiments (mean with 95% CI) in the same animals as described in the legend to Fig. 1. Statistical significance is given for the difference
between the positive control and the treatment group
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IL-12p40: In the positive control group, IL-12p40 in-
creased from mean 0.5 (±0.01) ng/mL at T0 to 1.8 (±0.3)
ng/mL at T120 and 10.0 (±2.5) ng/mL at T180 (Fig. 2).
In the treatment group, IL-12p40 increased from mean
0.4 (±0.01) ng/mL at T0 to 0.7 (±0.1) ng/mL at T120
and 5.4 (±1.2) ng/mL at T180. The difference between
the group was statistically significant (p = 0.03), and the
AUC was 50% lower in the treatment group than the
positive control group. No increase was seen in sham
animals.
IFN-α and IL-4 were not increased in any of the groups
(data not shown).
Granulocyte activation
wCD11R3: In the positive control group, wCD11R3
increased from mean MFI 51 (±9) at T0 to MFI 700
(±150) at T180, whereas in the treatment group
wCD11R3 increased from mean MFI 46 (±14) at T0 to
MFI 568 (±68) at T180 (Fig. 3). The difference between
the two groups was significant (p = 0.01).
Discussion
Fulminant meningococcal sepsis is associated with a
massive, rapid, and harmful inflammatory activation that
is rarely seen in other conditions. CD14-mediated activa-
tion of the Toll-like receptor system and activation of
complement are the two best characterized parts of the
innate immune system participating in this inflammatory
response. Previously, we have performed extensive studies
on the effect of blocking CD14 and complement individu-
ally and together in both in vitro and in vivo inflammatory
models [10, 18, 32]. The results from these studies have
clearly demonstrated attenuation of the inflammatory re-
sponse when these two parts of the innate immune system
are blocked together, compared to separate blocking.
Thus, based on the previous studies, and not least in order
to limit the total number of animals used, this study was
designed to investigate only the effect of combined CD14
and complement inhibition in meningococcal sepsis. This
combined blocking of C5 and CD14 significantly and effi-
ciently attenuated the inflammatory response induced by
N. meningitidis in vivo.
Sustained high-grade activation of complement con-
tinuing until death despite optimal antibiotic and
conventional supportive treatment is a characteristic for
non-surviving patients with fulminant meningococcal
sepsis [33]. Persistent high levels of complement-derived
inflammatory molecules may contribute to the develop-
ment of the systemic inflammatory response syndrome
(SIRS). The potent anaphylatoxin C5a is considered the
most important of these mediators, and thus blocking
complement at the level of C5 is an interesting approach
in fulminant meningococcal sepsis. Abolished delivery of
C5a will attenuate the inflammatory response, while sim-
ultaneous administration of antibiotic treatment ensures
killing of meningococci despite the lack of C5b-9 lysis.
Also, activation of complement C3 is maintained when
C5 is blocked, leaving C3-mediated opsonophagocytosis
active for clearance of bacteria.
In the present study, we reproduced the systemic
complement activation seen in patients with fulminant
meningococcal sepsis. For the first time, it is demon-
strated that this complement activation can be efficiently
abolished by a C5 inhibitor in vivo, suggesting that such
treatment can have a potential role as adjuvant treat-
ment in patients with fulminant meningococcal sepsis.
Combined treatment with C5 and CD14 inhibition
was applied to tackle two important inflammatory
mechanisms at the earliest possible stage during immune
recognition of meningococci. The goal of inhibiting the
innate immune response in cases of fulminant meningo-
coccal sepsis should be to interfere with the initial pro-
inflammatory signals. This is to avoid further escalation
of the cytokine response and prevent development of
“point of no return.” Then it is impossible to reverse the
highly disturbed pathophysiology of this condition. Pres-
ently, the most effective method to downregulate plasma
cytokine level in patients with fulminant meningococcal
sepsis is appropriate antibiotic treatment. The bacterial
load as determined by number of N. meningitidis DNA
molecules per milliliter plasma is reduced by 50% within
3 to 4 h after initiation of antibiotic treatment [34]. In
parallel, key inflammatory cytokines and chemokines are
Fig. 3 wCD11R3 expression on the surface of granulocytes (mean
with 95% CI) was measured by flow cytometry at baseline (Tbasis)
and at the end of the experiment (T180) in the same animals as
described in the legend to Fig. 1. Statistical significance is given
for the difference in MFI between the positive control and the
treatment group at T180
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reduced by 50% in plasma within 1 to 3 h [35, 36]. Even
though the present study simulated a situation without
antibiotics and escalating number of meningococci, the
combined blocking of C5 and CD14 alone obtained a
substantial attenuation of the release of several key cyto-
kines, i.e., INF-γ, TNF, IL-8, IL-10, and IL-12p40. Our
present experiments suggest that combined C5 and
CD14 inhibition might reduce the cytokine production
in patients and add to the effect of antibiotics per se.
The inhibitory effects on TNF and IL-10 by the
combined treatment are of particular interest. TNF was
efficiently but transiently inhibited in the initial phase, in
a way that abolished the high peek in TNF concentration
otherwise seen in the positive control group as well as in
previous studies [18, 21]. TNF is a strong inductor of
the acute phase response in SIRS and is the most
extensively studied cytokine in sepsis [37]. High levels of
TNF in the initial phase of sepsis have been associated
with early hemodynamic deterioration [37, 38]. Thus,
attenuated increase of TNF in the initial phase of sepsis
development may be particularly beneficial. There is evi-
dence that with progression of sepsis anti-inflammatory
mechanisms become increasingly important [37, 39, 40].
IL-10 is the most potent anti-inflammatory cytokine,
being substantially increased in meningococcal sepsis
[41–43]. Sustained high levels of IL-10, and in particular
sustained high IL-10/TNF ratio have been demonstrated
to be associated with high mortality in meningococcal
sepsis as well as in other infectious diseases [39, 44, 45].
IL-10 is responsible for extensive changes in the func-
tion of monocytes in meningococcal sepsis [43, 46].
Based on these observations, we assume that it may be
beneficial to decrease the level of IL-10 in meningococ-
cal sepsis, like we obtained with the combined treatment
in this study. Furthermore, we suggest that the balance
between TNF and IL-10 may be altered in a favorable
way in the initial as well as later stages of sepsis develop-
ment by the combined treatment. This may be in con-
trast to isolated inhibition of pro-inflammatory cytokines
like TNF and IL-1β, which has been tried without
success [40]. Given the substantial amounts of cytokines
released “downstream” of the innate immune recogni-
tion phase, it is perhaps not surprising that inhibition of
only one of these does not have an effect on the clinical
course of the fulminant form of the disease. Thus,
“upstream” inhibition of bottle-neck molecules of the
main pattern recognition systems, like complement and
CD14/TLRs, is a rational approach for broad-acting
attenuation of the inflammatory response induced by
meningococci.
Further, we suggest that the efficient inhibition of the
chemokine IL-8 that we obtained initially in this study
can be beneficial with respect to the prognosis. High
levels of IL-8 have been described to predict fatal sepsis
[47–50]. IL-8 attracts leukocytes to the site of inflamma-
tion, and high levels of IL-8 are likely to contribute to
the profound leukopenia characteristic of severe menin-
gococcal sepsis.
The significantly reduced expression of granulocyte
wCD11R3 (the porcine ortholog to human CD11b) in
the treatment group implies that combined treatment
influenced white blood cell function not only by decreas-
ing cytokine release but also by decreasing expression of
surface molecules. In complex with CD18, wCD11R3
constitutes complement receptor 3 (CR3), which is ac-
tive in phagocytosis of bacteria. Phagocytosis per se is
obviously beneficial in meningococcal disease in order to
clear bacteria from the circulation. However, it does not
need to be as efficient in the presence of antibiotics, and
a limited decrease of phagocytosis may possibly be
beneficial due to less induced oxidative burst, which
otherwise may be harmful to surrounding tissue [32].
Conclusions
We suggest that the course of meningococcal sepsis
observed in piglets in the present study represents a
realistic model of the situation in patients with fulmin-
ant meningococcal sepsis. We demonstrate that efficient
complement inhibition can be obtained in this model.
Furthermore, we find that combined inhibition of the
two key innate immune systems, complement with the
central component C5 and the TLRs with the co-receptor
CD14, can modulate the inflammatory response in ful-
minant meningococcal sepsis, provided the C5 and CD14
inhibition is initiated early. Modulation of this inflamma-
tory response may be of potential benefit in patients with
meningococcal sepsis.
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